Simvastatin and GGTI-2133, a geranylgeranyl transferase inhibitor, increase erythrocyte deformability but reduce low O2 tension-induced ATP release

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 5, 2013, Pages

  Clapp, K M ^a   Ellsworth, M L ^a   Sprague, R S ^a   Stephenson, A H ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Isoproterenol; Mastoparan 7; Red blood cell

Indexed keywords

ADENOSINE TRIPHOSPHATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GGTI 2133; HEMOGLOBIN; MASTOPARAN; RHO KINASE; SIMVASTATIN; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; ERYTHROCYTE; ERYTHROCYTE DEFORMABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; OXYGEN DESATURATION; OXYGEN TENSION; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATE; ADRENERGIC BETA-AGONISTS; ADULT; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTES; FEMALE; HUMANS; IMIDAZOLES; ISOPROTERENOL; LEUCINE; MALE; MIDDLE AGED; NAPHTHALENES; NITRIC OXIDE SYNTHASE TYPE III; OXYGEN; PARTIAL PRESSURE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; SIMVASTATIN; WASP VENOMS; YOUNG ADULT;

EID: 84874633240     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00635.2012     Document Type: Article

References (49)

1. An SS, Pennella CM, Gonnabathula A, Chen J, Wang N, Gaestel M, Hassoun PM, Fredberg JJ, Kayyali US. Hypoxia alters biophysical properties of endothelial cells via p38 MAPK-and Rho kinase-dependent pathways. Am J Physiol Cell Physiol 289: C521-C530, 2005.
2. Bergfeld GR, Forrester T. Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res 26: 40-47, 1992.
3. Bhandary S, Basu R, Das S, Nandy P. Effect of some statin group of drugs on the phase profile of liposomal membrane-a fluorescence anistropy study. Phase Transit 82: 821, 2009.
4. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 43: 269-287, 1999.
5. Caliskan S, Caliskan M, Kuralay F, Onvural B. Effect of simvastatin therapy on blood and tissue ATP levels and erythrocyte membrane lipid composition. Res Exp Med (Berl) 199: 189-194, 2000.
6. Chalmers C, Bird BD, Whitwam JG. Evaluation of a new thin film tonometer. Br J Anaesth 46: 253-259, 1974.
7. Chu H, Breite A, Ciraolo P, Franco RS, Low PS. Characterization of the deoxyhemoglobin binding site on human erythrocyte band 3: implications for O2 regulation of erythrocyte properties. Blood 111: 932-938, 2008.
8. Dessauer C, Posner BA, Gilman AG. Visulaizating signal transduction: receptors, G-proteins, and adenylate cyclases. Clin Sci 91: 527-537, 1996.
9. Ellis CG, Goldman D, Hanson M, Stephenson AH, Milkovich S, Benlamri A, Ellsworth ML, Sprague RS. Defects in oxygen supply to skeletal muscle of prediabetic ZDF rats. Am J Physiol Heart Circ Physiol 298: H1661-H1670, 2010.
10. Ellsworth ML, Ellis CG, Goldman D, Stephenson AH, Dietrich HH, Sprague RS. Erythrocytes: oxygen sensors and modulators of vascular tone. Physiology 24: 107-116, 2009.
11. Forsyth AM, Braunmuller S, Wan J, Franke T, Stone HA. The effects of membrane cholesterol and simvastatin on red blood cell deformability and ATP release. Microvasc Res 83: 347-351, 2012.
12. Fukata Y, Oshiro N, Kaibuchi K. Activation of moesin and adducin by Rho-kinase downstream of Rho. Biophys Chem 82: 139-147, 1999.
13. Fukata Y, Oshiro N, Kinoshita N, Kawano Y, Matsuoka Y, Bennett V, Matsuura Y, Kaibuchi K. Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. J Cell Biol 145: 347-361, 1999.
14. Gautam N, Downes GB, Yan K, Kisselev O. The G-protein βγ complex. Cell Signal 10: 447-455, 1998.
15. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 64: 102-146, 2012.
16. Gudi SR, Clark CB, Frangos JA. Fluid flow rapidly activates G proteins in human endothelial cells. Involvement of G proteins in mechanochemical signal transduction. Circ Res 79: 834-839, 1996.
17. Holownia P, Bishop E, Newman DJ, John WG, Price CP. Adaptation of latex-enhanced assay for percent glycohemoglobin to a Dade dimension analyzer. Clin Chem 43: 76-84, 1997.
18. Inman SR, Caprio TW, Drummond E, Mueller M, Entenman K. Enhanced acetylcholine-induced dilation in afferent arterioles in simvastatin-fed rats. Vasc Pharmacol 44: 17-21, 2006.
19. Ito D, Ito O, Mori N, Muroya Y, Cao PY, Takashima K, Kanazawa M, Kohzuki M. Atorvastatin upregulates nitric oxide synthases with Rhokinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats. J Hypertens 28: 2278-2288, 2010.
20. Ito S, Majumdar A, Kume H, Shimokata K, Naruse K, Lutchen KR, Stamenovic D, Suki B. Viscoelastic and dynamic nonlinear properties of airway smooth muscle tissue: roles of mechanical force and the cytoskeleton. Am J Physiol Lung Cell Mol Physiol 290: L1227-L1237, 2006.
21. Jacot JG, McCulloch AD, Omens JH. Substrate stiffness affects the functional maturation of neonatal rat ventricular myocytes. Biophys J 95: 3479-3487, 2008.
22. Jagger JE, Bateman RM, Ellsworth ML, Ellis CG. Role of erythrocyte in regulating local O2 delivery mediated by hemoglobin oxygenation. Am J Physiol Heart Circ Physiol 280: H2833-H2839, 2001.
23. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Posttranslational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6: 541-555, 2007.
24. Krause BR, Newton RS. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 117: 237-244, 1995.
25. Lee JS, Panorchan P, Hale CM, Khatau SB, Kole TP, Tseng Y, Wirtz D. Ballistic intracellular nanorheology reveals ROCK-hard cytoplasmic stiffening response to fluid flow. J Cell Sci 119: 1760-1768, 2006.
26. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100: 178-184, 1999.
27. Liang K, Kim CH, Vaziri ND. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol 288: F539-F544, 2005.
28. Losapio JL, Sprague RS, Lonigro AJ, Stephenson AH. 5,6-EETinduced contraction of intralobar pulmonary arteries depends on the activation of Rho-kinase. J Appl Physiol 99: 1391-1396, 2005.
29. Mohandas N, Chasis JA. Red blood cell deformability, membrane material properties and shape: regulation by transmembrane, skeletal and cytosolic proteins and lipids. Seminars in Hematology 30: 171-192, 1993.
30. Myung CS, Yasuda H, Liu WW, Harden TK, Garrison JC. Role of isoprenoid lipids on the heterotrimeric G protein subunit in determining effector activation. J Biol Chem 274: 16595-16603, 1999.
31. Nohria A, Prsic A, Liu PY, Okamoto R, Creager MA, Selwyn A, Liao JK, Ganz P. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205: 517-521, 2009.
32. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95: 1126-1131, 1997.
33. Olearczyk JJ, Stephenson AH, Lonigro AJ, Sprague RS. Heterotrimeric G protein Gi is involved in a signal transduction pathway for ATP release from erythrocytes. Am J Physiol Heart Circ Physiol 286: H940-H945, 2004.
34. Olearczyk JJ, Stephenson AH, Lonigro AJ, Sprague RS. Receptormediated activation of the heterotrimeric G-protein Gs results in ATP release from erythrocytes. Med Sci Monit 7: 669-674, 2001.
35. Oschry Y, Eisenberg S. Rat plasma lipoproteins: re-evaluation of a lipoprotein system in an animal devoid of cholesteryl ester transfer activity. J Lipid Res 23: 1099-1106, 1982.
36. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 97: 1232-1235, 2005.
37. Shaw A, Xu Q. Biomechanical stress-induced signaling in smooth muscle cells: an update. Curr Vasc Pharmacol 1: 41-58, 2003.
38. Sprague R, Bowles E, Stumpf M, Ricketts G, Freidman A, Hou WH, Stephenson A, Lonigro A. Rabbit erythrocytes possess adenylyl cyclase type II that is activated by the heterotrimeric G proteins Gs and Gi. Pharmacol Rep Suppl 57: 222-228, 2005.
39. Sprague RS, Ellsworth ML, Stephenson AH, Kleinhenz ME, Lonigro AJ. Deformation-induced ATP release from red blood cells requires CFTR activity. Am J Physiol Heart Circ Physiol 275: H1726-H1732, 1998.
40. Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ. ATP: the red blood cell link to NO and local control of the pulmonary circulation. Am J Physiol Heart Circ Physiol 271: H2717-H2722, 1996.
41. Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ. Participation of cAMP in a signal-transduction pathway relating erythrocyte deformation to ATP release. Am J Physiol Cell Physiol 281: C1158-C1164, 2001.
42. Sridharan M, Sprague RS, Adderley SP, Bowles EA, Ellsworth ML, Stephenson AH. Diamide decreases deformability of rabbit erythrocytes and attenuates low oxygen tension-induced ATP release. Exp Biol Med (Maywood) 235: 1142-1148, 2010.
43. Stefanovic M, Puchulu-Campanella E, Kodippili G, Low PS. Oxygen regulates the band 3-ankyrin bridge in the human erythrocyte membrane. Biochem J 449: 143-150, 2013.
44. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001.
45. Targos B, Pomorski P, Krzeminski P, Baranska J, Redowicz MJ, Klopocka W. Effect of Rho-associated kinase inhibition on actin cytoskeleton structure and calcium response in glioma C6 cells. Acta Biochim Pol 53: 825-831, 2006.
46. Thuet KM, Bowles EA, Ellsworth ML, Sprague RS, Stephenson AH. The Rho kinase inhibitor Y-27632 increases erythrocyte deformability and low oxygen tension-induced ATP release. Am J Physiol Heart Circ Physiol 301: H1891-H1896, 2011.
47. Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J Med Chem 42: 1333-1340, 1999.
48. Wedegaertner PB, Wilson PT, Bourne HR. Lipid modifications of trimeric G proteins. J Biol Chem 270: 503-506, 1995.
49. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 97: 105-116, 2002.